The participating healthcare professionals, who practice in ten Central and Eastern European Countries (Austria, Bosnia and Herzegovina, Bulgaria, Croatia, Estonia, Hungary, Latvia, Romania, Serbia, and Slovenia), discussed topics such as diagnostic methods, epidemiology, and treatment options for patients with NSCLC, including those with EGFR exon 20 insertion mutations. This evidence concerns the gene EGFR and non-small cell lung carcinoma.